Key Takeaways
- Strong quarter, broad-based growth: Revenue rose 36% YoY to INR 809 crore, with domestic organic growth in mid-teens outpacing the industry and CMO revenues hitting an all-time high.
- Acquired brands are scaling fast: The Sanzyme and Azmarda portfolios grew 25% in Q2, with Sporlac up 50% and Azmarda up 46%, validating the integration thesis and prescriber synergy.
- CMO business is inflecting: Lozenge production doubled YoY to 9 crore units per month, and management now targets this segment to become a $100 million, 20%-of-revenue business over the mid-to-long term.
- Margins held despite cost and mix pressure: Gross margin dipped to 63% from 65% on input inflation and low-margin Azmarda, but EBITDA margin guidance of 24–26% for FY23 was reaffirmed.
- What to watch next quarter: The Azmarda loss-of-exclusivity transition and its cooling-period impact on volumes, the trajectory of input costs now described as "peaked," and whether CMO lozenge demand sustains at the elevated 9-crore monthly run-rate.
Domestic Formulations: Organic Engine & Brand Momentum
- Outpacing the market: Mid-teens organic growth kept JB as the fastest-growing company in the IPM top 25 per IQVIA MAT September 2022 data, driven by both acute and chronic portfolios.
- Prescription volume surge: Quarterly prescriptions jumped 55% YoY to 4.12 crore, with mass brands benefiting from a dominant acute season and the acquired portfolio adding roughly 30 lakh monthly prescriptions.
- Chronic mix shift adds stability: Chronic contribution rose to ~52% from ~45% a year ago, reducing dependence on seasonal acute demand; Cilacar-T, a drug of choice for diabetic hypertensive patients, grew 30% and is nearing a INR 120 crore run-rate.
- Key brand rankings improved sharply: Metrogyl gained 56 ranks to 149, Cilacar-T gained 76 ranks to 212, Nicardia gained 27 ranks to 218, while Cilacar and Rantac held strong at ranks 48 and 41 respectively.
- Respiratory franchise building out: New launches VISCOJOY and Akair LC are each close to a INR 6 crore run-rate; half a dozen nebulized products were launched with traction expected in the November-to-February period.
- Pediatric portfolio taking shape: The mix now spans Rantac syrup, Laxolite, Zecuf, and acquired Dr. Reddy's brands (Z&D combination, Pecef antibiotic), with management noting good prescription traction from pediatricians that "should only improve."
- Ranitidine regulatory tailwind: The government removed Ranitidine from DPCO price control alongside ~25 other mature products, a move management links to supply continuity considerations given spiked material costs.
Chopra: "100% if you look at the medical fertility and with what we have done in the era of heart failure, the agenda going ahead is to prevent the progression of hypertension to heart failure."
Acquired Portfolios: Integration Payoff & LOE Opportunity
- Sanzyme portfolio outperforming: Sporlac grew 50% and retained its #1 rank, driven by prescriber-base synergy from JB's experience with mass brands like Rantac and Metrogyl, improved share of voice, and life cycle management. Other Sanzyme assets (Lobun, Oxalo, infertility portfolio) also delivered a good revenue jump.
- Azmarda scaling ahead of LOE: The brand grew 46% and entered the IPM Top 300 list in September 2022, supported by a 200-person field force and rising diagnosis rates via point-of-care 2D/3D Echo in cardiologist clinics.
- LOE as volume opportunity: Management expects 50–70 competing brands to enter post-LOE, driving therapy costs down and volumes up by two to three times over the next year; local sourcing options are expected to improve margins despite price erosion, leaving JB in a better margin position overall.
- Cooling-period mechanics: A 10–15 day cooling period is planned to liquidate existing channel stock before refilling at new prices; strong secondary demand means channel inventory is not significantly high, so the transition should be contained to a couple of weeks.
- Sporlac line extensions: A sachet version (Sporlac GG) was launched for pediatricians, with one or two more versions planned for gastroenterology and women's healthcare.
Chopra: "Post LOE, what is going to happen... we will see an influx of around 50, 70 Brands coming in. Overall, the cost of therapy will come down. Volumes over a period of time in the next year should go up by two to three times. So, we see a huge opportunity."
Khanna: "Overall, from a margin standpoint, we will still be at a better position despite this price erosion, because we will be looking at local sourcing options."
CMO Business: Capacity Inflection & Strategic Ambition
- Record quarter: CMO revenues were the highest ever, up 64% YoY, translating into the best-ever international sales; post-COVID demand for anti-inflammatory lozenges remains strong.
- Production doubled: Lozenge output rose from 4.5–5 crore units per month last year to 9 crore per month over the last three to four months, with packaging debottlenecking underway to reach 12 crore per month in the next two to three months and ultimately 15–16 crore.
- Strategic target raised: Management now wants CMO to become a close-to-$100 million business contributing 20% of overall JB revenue over the mid-to-long term, with growth expected to be higher than previously guided.
- Portfolio broadening beyond cough and cold: Life cycle management work is ongoing for big brands supplied to principal partners, extending into immunity, sleep, and motion sickness, all under development with partners.
- Order book visibility: The order book for Q3 and Q4 is healthy, and fundamental developmental work continues to extend the offering.
Chopra: "We want this business to be close to $100 million for us, and we want this business to contribute mid to long-term 20% to overall JB business."
International Formulations: Steady, With Selective Caution
- Double-digit performance overall: South Africa and Russia performed as per expectations, while ROW markets returned to double-digit growth in Q2 after a period of flat growth.
- Currency tailwind: Export formulations constant-currency growth included five to six points from currency gains, with the balance largely from volume; management declined to provide the exact constant-currency figure or geography-wise splits when asked.
- South Africa a key driver: Growth is coming from both public and private sides, and the market remains a focus area alongside Asia Pac, Middle East, and Africa.
- Russia approach stays cautious: No significant investment is planned given the external market situation, though performance is meeting expectations.
- H2 outlook: Rest-of-year growth is expected in the mid-teens across markets, with a combination of ROW, U.S., Russia, and South Africa contributing; new product filings will be made to commercialize over the next two to three years.
Margins & Costs: Peaked Pressure, Steady Outlook
- Gross margin compression: 63% vs 65% YoY, hit by inflationary pressure on input and packing material costs plus the low-margin Azmarda mix; material costs as a basket have not seen significant cooling, though aluminum has softened.
- Costs described as peaked: Input costs have largely peaked and are now in the P&L; management expects them to remain stable for Q3 and Q4, with no moderation yet seen in Metronidazole API costs specifically.
- Other expenses improved: Despite normalization of marketing spend from a low COVID base and higher utility and fuel prices, other expenses improved as a percentage of sales.
- Depreciation elevated: Higher depreciation during the quarter reflects amortization of acquired brands.
- Cash flow healthy: Sturdy cash generation in H1 FY23 with healthy EBITDA-to-free-cash-flow conversion; working capital metrics including inventory and receivables improved versus March 2022.
- ESOP cost trajectory: A step decrease is expected: INR 38–40 crore in FY24, declining to INR 25–30 crore in FY25.
Capital Allocation & M&A: Conservative, With Ambition
- M&A pipeline active: The company is evaluating inorganic opportunities with a preference for cardiology, pediatrics, nephrology, and respiratory; acquired businesses would not require additional MRs for 3 to 12 months.
- Full-company acquisitions on the table: Management is open to acquiring full-fledged companies if an opportunity makes strategic and financial sense, not just brand portfolios.
- Conservative leverage philosophy: While no specific debt metric was disclosed, management committed to being "very, very conservative relative to usual industry thresholds on debt to EBITDA" and does not want to stretch the balance sheet; funding would balance own generated capital and debt.
- New therapy launches: Dydrogesterone was launched in the IVF/Gynae space, breaking into a market previously monopolized by a large multinational, and is doing reasonably well; the portfolio will continue broadening beyond core hormone and IVF therapy.
Kataria: "We are open to acquiring companies as well. It is a matter of, you know, what opportunity comes our way that makes strategic and financial sense."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic revenue growth | Continue to outperform market growth via organic and inorganic mix | Sustained |
| EBITDA margin | Maintain 24–26% range with focus on revenue growth | FY23 |
| MR productivity | Reach close to INR 6.5 lakh | End of FY23 |
| CMO lozenge capacity | Reach 12 crore lozenges/month after packaging debottlenecking | Next 2–3 months |
| CMO lozenge capacity | Reach 15–16 crore lozenges/month | After further debottlenecking (undated) |
| CMO business size | Close to $100 million, 20% of overall JB business | Mid-to-long term |
| Export formulations growth | Mid-teens across markets | Rest of FY23 |
| Azmarda LOE cooling period | Restrict to ~2 weeks to liquidate existing stock | At LOE event |
| Top-line and profit growth aspiration | Mid-teens top-line (14–16%), profit growth better than top line (16–18%) | Next 2–3 years |
| ESOP cost | INR 38–40 crore | FY24 |
| ESOP cost | INR 25–30 crore | FY25 |
| Gross margin input costs | Remain stable at current levels | Q3 and Q4 FY23 |
| International filings | New product filings to commercialize in existing markets | Next 2–3 years |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹809 cr, +36% YoY |
| Domestic revenue | ₹434 cr |
| Domestic organic growth | Mid-teens |
| International business revenue | ₹375 cr, +28% YoY |
| Domestic/international revenue mix | 46/54 |
| Gross margin | 63%, flat QoQ, vs 65% in Q2 FY22 |
| Operating EBITDA | ₹202 cr, +44% YoY from ₹140 cr |
| Profit after tax | ₹111 cr, +13% YoY from ₹98 cr |
| EBITDA margin guidance for FY23 | 24% to 26% |
| Top-line growth aspiration (2-3 years) | 14% to 16% |
| Bottom-line growth aspiration (2-3 years) | 16% to 18% |
| CMO revenue growth | 64% YoY |
| CMO share of international sales (H1 FY23) | 28%, up from 20% in FY22 |
| Acquired brands portfolio growth (IQVIA, like-to-like) | 25% |
| Sporlac growth (IQVIA) | 50%, retained #1 rank in covered market |
| Azmarda growth (IQVIA) | 46% |
| Total prescriptions | 4.12 cr, +55% YoY from 2.65 cr |
| Monthly prescription run-rate (with acquired portfolio) | 1.5 cr |
| Chronic contribution to domestic portfolio | ~52%, up from ~45% 1-1.5 years ago |
| MR productivity target (FY23 end) | ~₹6.5 lakh |
| Total medical reps | 2,100 (1,600 organic, 300 Sanzyme, 200 Azmarda) |
| Borrowings (end of Sep '22) | ₹350 cr, up from ₹26 cr as of Mar '22 |
| Cash and investments (end of Sep '22) | ₹203 cr, up from ₹57 cr as of Mar '22 |
| Cash from operations (H1 FY23) | ~₹280 cr |
| ESOP cost (Q2 FY23) | ~₹18 cr |
| ESOP cost guidance (FY23) | ~₹71 cr |
| ESOP cost guidance (FY24) | ₹38-40 cr |
| ESOP cost guidance (FY25) | ₹25-30 cr |